ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy of bismuth-based quadruple therapy as the first-line treatment for H.pylori infection.</p><p><b>METHODS</b>A total of 136 patients with H.pylori related peptic ulcer or chronic gastritis were randomized into two groups: 67 patients in bismuth-based quadruple group received esomeprazole 20 mg, clarithromycin 0.5 g,amoxicillin 1.0 g,and bismuth potassium citrate 220 mg for 7 d; 69 patients in standard triple group received esomeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1.0 g for 7 d. Outcome of eradication therapy was assessed by (14)C-UBT. On ITT and PP analysis, calculating the cost-effectiveness ratio (C/E) and the incremental cost-effectiveness ratio (delta C/delta E).</p><p><b>RESULT</b>On ITT and PP analysis, the eradication rates of the quadruple therapy group were 82.09% and 88.71%, and those of the triple therapy group were 66.67% and 73.02% (P<0.05). The cost-effectiveness ratio of two groups was 4.15 and 4.82; The incremental cost-effectiveness ratio of quadruple therapy group was 1.02 as against triple therapy group.</p><p><b>CONCLUSION</b>Compared to the standard triple therapy regimen, the bismuth-containing quadruple therapy regimen has higher eradication rate and cost-effectiveness, which can be recommended as the fist-line treatment for H.pylori infection.</p>
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Anti-Bacterial Agents , Economics , Therapeutic Uses , Anti-Ulcer Agents , Economics , Therapeutic Uses , Bismuth , Economics , Therapeutic Uses , Cost-Benefit Analysis , Drug Therapy, Combination , Economics , Follow-Up Studies , Helicobacter Infections , Drug Therapy , Treatment OutcomeABSTRACT
OBJECTIVE@#To understand the prevalence of H.pylori infection in patients with cirrhosis, and liver cirrhosis with hepatocellular carcinoma(HCC), and to investigate the relationship between H.pylori infection and liver cirrhosis, and liver cirrhosis with hepatocellular carcinoma in patients.@*METHODS@#Serum anti-H.pylori antibodies IgG (HpIgG) was measured by dot immunogold filtration assay (DIGFA) in 101 liver cirrhosis and 42 liver cirrhosis with hepatoma patients and alpha-fetopro-tei(AFP)was determined by chemiluminescence.@*RESULTS@#HpIgG seroprevalence was 42.57% (43/101) in the liver cirrhosis patients, and 69.05% (29/42) in the liver cirrhosis with the HCC patients. HpIgG seropositivity in the liver cirrhosis with the HCC patients was higher than in those without HCC. HpIgG seropositivity in the HBV positive patients was higher than in the HBV negative patients (chi2=4.164, P=0.041). HpIgG seropositivity in the AFP abnormal patients was higher than in the AFP normal patients (chi2=4.695, P=0.030).@*CONCLUSION@#H.pylori may be a risk factor in patients with cirrhosis and HCC.